{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:30:54Z","timestamp":1793212254431,"version":"4.5.0"},"reference-count":13,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aggressive lymphomas are curable with doxorubicin-based chemotherapy. In patients presenting with elevated serum bilirubin, doxorubicin is commonly dose reduced or delayed based on limited pharmacokinetic data. We evaluated plasma pharmacokinetics of doxorubicin and its metabolite doxorubicinol as well as toxicity in 59 patients with normal bilirubin levels and 10 patients with elevated bilirubin levels. Patients received full-dose EPOCH +\/\u2212rituximab. Median (range) age was 51 (18-75) years. Patients with elevated bilirubin levels had higher international prognostic index and poorer performance status. Although median doxorubicin clearance was lower and median plasma doxorubicin and doxorubicinol concentrations were higher in patients with elevated bilirubin levels, values were within the concentration range observed in patients with normal levels. Rates of febrile neutropenia were similar between groups, but there was greater grade 4 neutropenia and thrombocytopenia during the first but not subsequent treatment cycles in patients with elevated bilirubin. More grade 3\/4 gastrointestinal and neurotoxicity occurred in patients with elevated bilirubin during the first but not subsequent cycles. Although toxicity was greater on cycle 1, the adverse effects were managed safely. These results show that empiric dose reductions of continuous infusion doxorubicin may not be necessary in patients with elevated bilirubin levels. This trial was registered at www.clinicaltrials.gov as #NCT00001337, #NCT00069238, and #NCT00005780.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007431","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T20:55:39Z","timestamp":1658868939000},"page":"529-532","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8861-0281","authenticated-orcid":false,"given":"Catherine","family":"Lai","sequence":"first","affiliation":[{"name":"1Division of Hematology-Oncology, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E.","family":"Cole","sequence":"additional","affiliation":[{"name":"2Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth M.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"2Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lucas","sequence":"additional","affiliation":[{"name":"2Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5323-6995","authenticated-orcid":false,"given":"Eva","family":"Dombi","sequence":"additional","affiliation":[{"name":"2Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9661-4570","authenticated-orcid":false,"given":"Christopher","family":"Melani","sequence":"additional","affiliation":[{"name":"2Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-2635","authenticated-orcid":false,"given":"Mark","family":"Roschewski","sequence":"additional","affiliation":[{"name":"2Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Balis","sequence":"additional","affiliation":[{"name":"3Children's Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[{"name":"2Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[{"name":"2Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"issue":"s3","key":"2023081515544303300_bib1","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.4081\/hr.2011.s3.e4","article-title":"Anthracyclines: a cornerstone in the management of non-Hodgkin\u2019s lymphoma","volume":"3","author":"Luminari","year":"2011","journal-title":"Hematol Rep"},{"issue":"1","key":"2023081515544303300_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/1097-0142(197401)33:1<19::AID-CNCR2820330107>3.0.CO;2-M","article-title":"Adriamycin chemotherapy: efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule","volume":"33","author":"Benjamin","year":"1974","journal-title":"Cancer"},{"issue":"5","key":"2023081515544303300_bib3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/bjc.1992.158","article-title":"Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters","volume":"65","author":"Johnson","year":"1992","journal-title":"Br J Cancer"},{"issue":"5","key":"2023081515544303300_bib4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/clpt.1993.69","article-title":"Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer","volume":"53","author":"Piscitelli","year":"1993","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2023081515544303300_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0959-8049(97)00340-7","article-title":"Pharmacokinetics of anticancer agents in patients with impaired liver function","volume":"34","author":"Donelli","year":"1998","journal-title":"Eur J Cancer"},{"issue":"1","key":"2023081515544303300_bib6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.seminoncol.2005.11.002","article-title":"Hepatotoxicity of chemotherapy","volume":"33","author":"Floyd","year":"2006","journal-title":"Semin Oncol"},{"issue":"1","key":"2023081515544303300_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/bjc.1995.278","article-title":"An evaluation of hepatic extraction and clearance of doxorubicin","volume":"72","author":"August","year":"1995","journal-title":"Br J Cancer"},{"issue":"8","key":"2023081515544303300_bib8","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood"},{"issue":"suppl 15","key":"2023081515544303300_bib9","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1200\/jco.2014.32.15_suppl.8547","article-title":"Pharmacokinetics and tolerability of doxorubicin in newly diagnosed lymphoma patients with hepatic impairment","volume":"32","author":"Lai","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023081515544303300_bib10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/clpt.1989.39","article-title":"Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin","volume":"45","author":"Ackland","year":"1989","journal-title":"Clin Pharmacol Ther"},{"issue":"21","key":"2023081515544303300_bib11","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood.V124.21.4445.4445","article-title":"Pharmacokinetics and tolerability of etoposide in newly diagnosed lymphoma patients with hepatic impairment","volume":"124","author":"Lai","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2023081515544303300_bib12","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1634\/theoncologist.12-9-1070","article-title":"Commentary: oncologic drugs in patients with organ dysfunction: a summary","volume":"12","author":"Superfin","year":"2007","journal-title":"Oncologist"},{"issue":"1","key":"2023081515544303300_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00685876","article-title":"Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit","volume":"32","author":"Cusack","year":"1993","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/4\/529\/2071288\/blooda_adv-2022-007431-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/4\/529\/2071288\/blooda_adv-2022-007431-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T11:56:33Z","timestamp":1692100593000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/4\/529\/486017\/Doxorubicin-pharmacokinetics-and-toxicity-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,2,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007431","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]}}}